Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right
Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. Read more ›
Genzyme Further Expands Biomanufacturing Plant in Belgium
Biotechnology company Genzyme announced today it will further expand its high-tech cell culture production facility in Geel, Belgium, with an additional bioreactor of 4000 liter. The investment for this amounts to €46 million euro, and eighty extra jobs will be created at the Geel site. Read more ›
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis
Genzyme Corporation announced today that it has entered into an agreement to acquire the worldwide rights to Campath®/Mabcampath® (alemtuzumab) from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization of this potential treatment for multiple sclerosis (MS). Read more ›
